home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

105.16 -0.33 (-0.31%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

February 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

January 11, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

January 04, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Expert Ratings For Mirum Pharmaceuticals ↗

September 30, 2021

Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst rat...

Via Benzinga

Mirum Pharmaceuticals Added to NASDAQ Biotechnology Index

December 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

LIVMARLI (maralixibat) Presentations Show Improvements in Quality of Life Measures in Alagille Syndrome and PFIC2 at NASPGHAN Annual Meeting 2021

December 13, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Present LIVMARLI™ (maralixibat) Analyses at NASPGHAN 2021 Annual Meeting

December 06, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 22, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher

November 17, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome

November 15, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call on November 15, 2021

November 08, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For November 15, 2021 ↗

November 15, 2021

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter. • Tyson Foods (NYSE:TSN) is estimated to...

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

New LIVMARLI™ (maralixibat) Data to be Showcased at AASLD The Liver Meeting® 2021

November 01, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

The Lancet Publishes Data From Mirum Pharmaceuticals' ICONIC Pivotal Study of Maralixibat (LIVMARLI) Treatment in Alagille Syndrome

November 01, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

10 Biggest Price Target Changes For Thursday ↗

September 30, 2021

Jefferies raised Perrigo Company plc (NYSE:PRGO) pr...

Via Benzinga

FDA Approves First Treatment For Alagille Syndrome-Associated Cholestatic Pruritus From Mirum Pharma ↗

September 29, 2021

The FDA has approved Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Livmarli (maralixibat) oral solution for cholestatic pruritus in patients with Alagille syndrome (...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 29, 2021

Gainers Regencell Bioscience (NASDAQ:RGC)...

Via Benzinga

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older

September 29, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Mirum, Takeda Ink Maralixibat Licensing Pact In Japan ↗

September 21, 2021

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) and Takeda Pharmaceutical Company Limited (NYSE: TAK) have entered into an exclusive licensing agreement for...

Via Benzinga

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

September 21, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

What 5 Analyst Ratings Have To Say About Mirum Pharmaceuticals ↗

September 20, 2021

Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed ...

Via Benzinga

Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study Comparison

September 13, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in September Investor Conferences

September 02, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates ↗

August 31, 2021

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New...

Via Benzinga

Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors

August 19, 2021

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com